Abeona Therapeutics Inc (NASDAQ:ABEO – Get Free Report) CFO Joseph Walter Vazzano purchased 5,608 shares of Abeona Therapeutics stock in a transaction on Thursday, April 25th. The stock was bought at an average price of $3.14 per share, with a total value of $17,609.12. Following the transaction, the chief financial officer now owns 233,868 shares of the company’s stock, valued at $734,345.52. The purchase was disclosed in a filing with the SEC, which is available through this hyperlink.
Abeona Therapeutics Price Performance
Shares of Abeona Therapeutics stock opened at $3.26 on Friday. Abeona Therapeutics Inc has a 12 month low of $2.83 and a 12 month high of $9.01. The stock has a 50 day moving average of $7.31 and a 200 day moving average of $5.61.
Abeona Therapeutics (NASDAQ:ABEO – Get Free Report) last issued its quarterly earnings results on Monday, March 18th. The biopharmaceutical company reported ($0.64) earnings per share (EPS) for the quarter, missing analysts’ consensus estimates of ($0.51) by ($0.13). As a group, analysts forecast that Abeona Therapeutics Inc will post -2.05 earnings per share for the current fiscal year.
Institutional Inflows and Outflows
Analysts Set New Price Targets
A number of analysts have commented on ABEO shares. StockNews.com cut Abeona Therapeutics from a “hold” rating to a “sell” rating in a research report on Tuesday. Cantor Fitzgerald reiterated an “overweight” rating and set a $36.00 target price on shares of Abeona Therapeutics in a research report on Tuesday.
Check Out Our Latest Research Report on Abeona Therapeutics
About Abeona Therapeutics
Abeona Therapeutics Inc, a clinical-stage biopharmaceutical company, focuses on developing and delivering gene therapy products for severe and life-threatening rare diseases. The company's lead programs are EB-101 (gene-corrected skin grafts) for recessive dystrophic epidermolysis bullosa (RDEB); ABO-102, which are AAV based gene therapies for Sanfilippo syndrome type A; and ABO-101, an adeno-associated virus (AAV) based gene therapies for Sanfilippo syndrome type B.
Read More
- Five stocks we like better than Abeona Therapeutics
- 3 Stocks to Protect Your Portfolio from the Coronavirus Contagion
- MarketBeat Week in Review – 4/22 – 4/26
- 5 discounted opportunities for dividend growth investors
- 3 Stocks Leading the U.S. Agriculture Comeback
- Low PE Growth Stocks: Unlocking Investment Opportunities
- How to Use Put Debit Spreads to Profit From Falling Stocks
Receive News & Ratings for Abeona Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Abeona Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.